Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
35.55
+0.92 (+2.66%)
Streaming Delayed Price
Updated: 10:59 AM EST, Feb 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
281,484
Open
34.38
Bid (Size)
35.39 (200)
Ask (Size)
35.71 (100)
Prev. Close
34.63
Today's Range
34.00 - 35.71
52wk Range
14.06 - 42.00
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
February 18, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Performance
YTD
+1.0%
+1.0%
1 Month
+9.7%
+9.7%
3 Month
-5.7%
-5.7%
6 Month
+45.5%
+45.5%
1 Year
+85.9%
+85.9%
More News
Read More
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 04, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 07, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
November 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November
October 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Deep Dive Into NewAmsterdam Pharma Co Stock: Analyst Perspectives (4 Ratings)
↗
October 20, 2025
Via
Benzinga
NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum
September 24, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Expert Outlook: NewAmsterdam Pharma Co Through The Eyes Of 6 Analysts
↗
August 25, 2025
Via
Benzinga
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
August 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib
August 18, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About NewAmsterdam Pharma Co
↗
August 07, 2025
Via
Benzinga
NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
↗
August 06, 2025
Via
The Motley Fool
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 06, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025
July 30, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
July 22, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Frequently Asked Questions
Is NewAmsterdam Pharma Company N.V. - Ordinary Shares publicly traded?
Yes, NewAmsterdam Pharma Company N.V. - Ordinary Shares is publicly traded.
What exchange does NewAmsterdam Pharma Company N.V. - Ordinary Shares trade on?
NewAmsterdam Pharma Company N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The ticker symbol for NewAmsterdam Pharma Company N.V. - Ordinary Shares is NAMS on the Nasdaq Stock Market
What is the current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares?
The current price of NewAmsterdam Pharma Company N.V. - Ordinary Shares is 35.55
When was NewAmsterdam Pharma Company N.V. - Ordinary Shares last traded?
The last trade of NewAmsterdam Pharma Company N.V. - Ordinary Shares was at 02/20/26 10:59 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
